ijms-logo

Journal Browser

Journal Browser

G Protein-Coupled Receptor Drug Discovery: Recent Advances and Future Perspectives

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 740

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
Interests: GPCR medicinal chemistry; innovative drug discovery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Key Laboratory of Chemical Biology (Ministry of Education), Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 West Culture Road, Jinan 250012, China
Interests: drug discovery; drug design; antiviral; HIV-1/AIDS
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As a family of widely distributed and multifunctional receptors on the cell membrane, G Protein-Coupled Receptors (GPCRs) are not only involved in the regulation of almost all the basic processes of life activities, from neurotransmission to immune response, from hormone secretion to cell proliferation, but have also become one of the most important families of drug targets in modern drug discovery and development. The aim of this Special Issue is to explore the potential of GPCRs as drug targets to analyze their structural and functional mechanisms, to share innovative drug design strategies, and to evaluate the preclinical and clinical results of new drugs.

In this Special Issue, original research articles and reviews are welcome to be submitted. Research areas may include, but are not limited to, the following:

  • New discoveries in GPCR structure and function;
  • GPCR-targeted drug design, synthesis, and optimization;
  • In-depth analysis of the relationship between GPCR signaling mechanisms and diseases;
  • GPCR-targeted drug screening platforms and technological innovations;
  • Preclinical evaluation and clinical trial progress of GPCR drugs;
  • Prospects and challenges of GPCR drugs in the treatment of specific/rare diseases.

Prof. Dr. Boshi Huang
Prof. Dr. Dongwei Kang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • GPCR drug discovery
  • GPCR therapeutics
  • drug design and synthesis
  • structural biology
  • preclinical evaluation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 2674 KiB  
Article
Novel Phenoxyalkanoic Acid Derivatives as Free Fatty Acid Receptor 4 Agonists for Treating Type 2 Diabetes Mellitus
by Xu Li, Xinmeng Zhang, Xueyuan Xie, Taimin Dong, Chengxu Lv, Ranran Guan, Wenyue Zhang, Guoxia Ji, Fanghui Chen, Shiben Wang and Xuekun Wang
Int. J. Mol. Sci. 2024, 25(21), 11476; https://doi.org/10.3390/ijms252111476 - 25 Oct 2024
Viewed by 529
Abstract
Diabetes mellitus (DM) is a common metabolic disease that poses a severe threat to human health. Despite a range of therapeutic approaches, there remains a lack of effective and safe therapies with the existing drugs. Therefore, there is an urgent need to develop [...] Read more.
Diabetes mellitus (DM) is a common metabolic disease that poses a severe threat to human health. Despite a range of therapeutic approaches, there remains a lack of effective and safe therapies with the existing drugs. Therefore, there is an urgent need to develop novel, effective, and safe therapeutic strategies for DM. Free fatty acid receptor 4 (FFAR4), also known as GPR120, is a member of the G protein-coupled receptor family, which has received considerable attention as an attractive new therapeutic target for treating DM. In the present study, based on the structure of TUG-891, which has excellent activity and selectivity, a series of novel FFAR4 agonists was designed by replacing the phenylpropanoic acid β position carbon atom with an oxygen atom, while replacing the linking oxymethylene with an amide-linking group. The target compounds were evaluated for FFAR4 agonistic activity, and the preferred compounds were evaluated for selectivity, oral glucose tolerance in normal ICR mice, antidiabetic activity in diet-induced obese (DIO) mice, pharmacokinetic properties in ICR mice and molecular modeling studies. The results showed that compound 10f possessed excellent FFAR4 agonistic activity and selectivity, significantly improved glucose tolerance in normal ICR mice, lowered blood glucose and promoted insulin secretion in a dose-dependent manner in DIO mice, and showed favorable pharmacokinetic properties. These results indicate that compound 10f may be a promising compound that deserves further structure–activity relationship and pharmacological studies for the development of antidiabetic drugs. Full article
Show Figures

Figure 1

Back to TopTop